Fidler, Trevor P. http://orcid.org/0000-0002-0758-9984
Xue, Chenyi
Yalcinkaya, Mustafa
Hardaway, Brian
Abramowicz, Sandra
Xiao, Tong http://orcid.org/0000-0003-1462-4650
Liu, Wenli
Thomas, David G.
Hajebrahimi, Mohammad Ali
Pircher, Joachim
Silvestre-Roig, Carlos
Kotini, Andriana G.
Luchsinger, Larry L.
Wei, Ying
Westerterp, Marit
Snoeck, Hans-Willem http://orcid.org/0000-0001-8375-995X
Papapetrou, Eirini P. http://orcid.org/0000-0001-7002-417X
Schulz, Christian http://orcid.org/0000-0003-3878-7833
Massberg, Steffen http://orcid.org/0000-0001-7387-3986
Soehnlein, Oliver http://orcid.org/0000-0002-7854-0694
Ebert, Benjamin http://orcid.org/0000-0003-0197-5451
Levine, Ross L. http://orcid.org/0000-0002-7884-1905
Reilly, Muredach P.
Libby, Peter http://orcid.org/0000-0002-1502-502X
Wang, Nan http://orcid.org/0000-0001-9976-0859
Tall, Alan R. http://orcid.org/0000-0002-7708-2417
Article History
Received: 28 September 2019
Accepted: 8 February 2021
First Online: 17 March 2021
Competing interests
: R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which include equity interest. He receives research support from and consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys and Novartis. He has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. P.L. is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron, and XBiotech, Inc. P.L. is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc. P.L.’s laboratory has received research funding in the last two years from Novartis. A.R.T. is a scientific advisory board member for Amgen, Staten Biotech and Fortico Biotech and is a consultant for Janssen, CSL and the Medicines Company. B.E. has research funding from Celgene and Deerfield, and consulting fees from Grail. E.P.P. has received honoraria from Celgene and Merck and research support from Incyte for research not related to this study.